JCHAIN and hepatocellular carcinoma: LGALS3BP, together with CD5 antigen like (CD5L) and immunoglobulin J chain (IGJ) constituted a triple-marker panel predictive of poor HCC survival and rapid progression after sorafenib treatment [44].